Choong ANG Vaccine Laboratory

072020 · KOSDAQ · ₩072020 · 중앙백신

₩8,870▲ ₩40 (0.45%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me

Valuation model · Discounted cash flow (DCF)

We use a 5-year discounted cash flow: the value of the cash the business is expected to produce, in today's money.

Fair value per share

₩10,883

vs the current price (₩8,870)

Enterprise value
₩78B
Equity value
₩101B
WACC
7.3%

Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal. This is not financial advice.

Bear / Base / Bull

Bear
₩7,537
−15.0%
Base
₩10,883
+22.7%
Bull
₩16,620
+87.4%

Bear: revenue growth 3 points lower every year, EBIT margin 2 points lower, WACC 1 point higher. Bull: the opposite.

Assumptions

Sign in to change the assumptions and see the results update. Sign in

Cycle options

Margin path

Every year uses the cycle-average margin (12.8%).

Revenue growth

  • 7.7%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.7% a year, annual reports), fading to 3% by year 5.

  • 6.5%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.7% a year, annual reports), fading to 3% by year 5.

  • 5.4%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.7% a year, annual reports), fading to 3% by year 5.

  • 4.2%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.7% a year, annual reports), fading to 3% by year 5.

  • 3%

    How much sales grow that year, compared with the year before.

    Default: the last 3 years' revenue growth (7.7% a year, annual reports), fading to 3% by year 5.

Business

  • 12.8%

    Operating profit as a share of revenue.

    Default: through-the-cycle average of the last 12 months and the last 5 annual reports' operating margins.

  • 27.5%

    Share of operating profit paid as corporate tax.

    Default: Korea's top corporate tax rate (25%) plus 10% local income tax.

  • 8.7%

    The non-cash cost of wearing out equipment, added back to cash flow (% of revenue).

    Default: not in the statements, so 80% of capital spending (most spending replaces equipment that wears out).

  • 10.8%

    Money spent on factories, equipment, software and other long-term assets (% of revenue).

    Default: average of the last 3 annual reports (cash flow statements; equipment and intangibles).

  • 33.4%

    Stock and unpaid customer bills, less unpaid supplier bills, as a % of revenue. Each year's extra revenue ties up this much more cash.

    Default: working capital (current assets less cash and deposits, minus current liabilities other than borrowings) as a share of revenue, averaged over the last 3 years.

Discount rate

  • 2%

    How fast cash flows keep growing every year after year 5.

    Default: about Korea's long-run inflation plus real growth.

  • 4.01%

    Yield on Korea's 10-year government bond: the return with almost no risk.

    Default: Korea Treasury Bond 10-year yield on 2026-10-30.

  • 0.6

    How much the share moves when the market moves: 1 means just like the market.

    Default: 105 weeks of weekly returns against KOSPI (official index); raw beta 0.08, adjusted toward 1 and kept between 0.6 and 2.0.

  • 5.5%

    The extra return investors want for owning shares instead of bonds.

    Default: a typical premium for Korean shares.

  • 5.51%

    The interest rate the company would pay to borrow.

    Default: the 10-year yield plus a 1.5% credit spread.

Starting point

Revenue (TTM to H1 2026)
₩48B
Net debt (borrowings and leases − cash and deposits)
−₩21B
+ Stakes and investments
₩1.9B
Associates, long-term financial assets and deposits (book value)
Shares
9,256,781
Share price
₩8,870
Market cap
₩82B

TTM = trailing 12 months: the last four reported quarters added together. "TTM to H1 2026" is the 12 months up to the latest quarterly or half-year report (H1 = to the end of June). Year 1 grows from there.

Past years and projection

Grey columns are reported results from the annual reports (after-tax EBIT at the model's tax rate), so you can check the growth and margin assumptions against the past. Years 1–5 are the model.

FY2023FY2024FY2025Year 1Year 2Year 3Year 4Year 5
Revenue₩42B₩46B₩49B₩52B₩55B₩58B₩61B₩63B
Growth6.7%8.9%7.6%7.7%6.5%5.4%4.2%3.0%
EBIT₩7B₩5.8B₩6.5B₩6.7B₩7.1B₩7.5B₩7.8B₩8B
EBIT margin16.7%12.6%13.2%12.8%12.8%12.8%12.8%12.8%
After-tax EBIT₩5.1B₩4.2B₩4.7B₩4.8B₩5.1B₩5.4B₩5.6B₩5.8B
+ Depreciation———₩4.5B₩4.8B₩5.1B₩5.3B₩5.4B
− Capital spending₩1.9B₩7.2B₩6B₩5.6B₩6B₩6.3B₩6.6B₩6.8B
− Working capital−₩10B−₩1.6B₩4.2B₩1.2B₩1.1B₩999M₩819M₩609M
Free cash flow———₩2.5B₩2.8B₩3.2B₩3.5B₩3.9B
Discount factor———0.9320.8680.8090.7540.703
Present value———₩2.3B₩2.5B₩2.6B₩2.7B₩2.7B

Terminal value ₩93B, worth ₩65B today: 84% of enterprise value. It assumes spending settles at 110% of depreciation once growth slows to the terminal rate.

Cross-check: what the market has paid before

For cyclical businesses, analysts check a DCF against the multiples the stock has traded at through past cycles. Price / book is the usual anchor for them: P/E looks highest at the bottom of a cycle, when earnings are smallest, and lowest at the top. The price each band would give today:

LowTypicalHigh
Price / book (book value ₩11,679 a share)Now 0.76×₩9,5650.82×₩11,5720.99×₩16,0571.37×
Price / earnings (last 12 months: ₩731 a share)Now 12.1×₩8,71211.9×₩11,08215.2×₩20,39427.9×

Low, typical and high are the 10th percentile, middle and 90th percentile of month-end multiples since 2021, each against the latest report out by then, per share at today's share count; loss years and P/E above 100 are left out. Run-rate earnings are one quarter × 4, not a forecast. Model estimate based on the assumptions shown. Not a price target and not a buy or sell signal.

Sensitivity

Fair value per share as two inputs change; the middle is the current case.

WACC ↓ · Terminal growth →1.0%1.5%2.0%2.5%3.0%
6.3%₩11,506₩12,169₩12,983₩14,010₩15,343
6.8%₩10,664₩11,190₩11,823₩12,601₩13,582
7.3%₩9,957₩10,381₩10,883₩11,487₩12,231
7.8%₩9,355₩9,701₩10,105₩10,585₩11,162
8.3%₩8,836₩9,122₩9,452₩9,838₩10,295

Now (TTM)

Market cap
₩82B
Enterprise value
₩61B
P/E
12.1×
P/B
0.8×
P/S
1.7×
EV/EBITDA
—
Dividend yield
0.0%

Over time (at each year end)

20252024202320222021
Price₩9,800₩9,800₩11,010₩11,000₩15,000
Market cap₩91B₩91B₩102B₩102B₩139B
P/E14.7×13.2×17.0×24.7×18.1×
P/B0.9×0.9×1.0×1.1×1.5×
P/S1.8×2.0×2.4×2.6×3.4×
EV/EBITDA—————
Dividend yield0.0%0.0%———

Versus similar companies

CompanyP/EP/BP/SEV/EBITDADividend yield
Choong ANG Vaccine Laboratory12.1×0.8×1.7×—0.0%
Samsung Biologics31.9×7.6×13.9×—0.0%
Celltrion27.9×2.5×9.0×—0.0%
Alteogen79.4×28.6×60.3×—0.1%
SK biopharmaceuticals15.2×6.0×7.1×—0.0%
Yuhan23.2×2.3×2.4×30.2×0.8%
HLB—15.4×54.3×—0.0%
Similar companies (median)27.9×6.8×11.4×30.2×0.0%

Calculated from end-of-day prices and filed financial statements. Not a recommendation. This is not financial advice.

Also known as: Choong ANG Vaccine Laboratory / 중앙백신 / 072020 / KRX:072020

Source: KRX statistical information